Abstract: Multiphasic nano-components (MPNs) having at least two phases and at least one active ingredient are provided. The MPNs can be used in various methods for medical diagnostics or with pharmaceutical, personal care, oral care, and/or nutritional compositions, for example, in oral care, hair, or skin products. The MPNs can be designed to have targeted delivery within an organism, while providing controlled release systems or combining incompatible active ingredients. Further, the MPNs can be used as biomedical coatings (such as anti-microbial coatings), or anti-corrosive coatings, bioimaging probes with combined diagnostic and therapeutic use, and fragrance release systems, among others. The MPNs can be formed by electrified jetting of polymers.

Abstract: The present invention provides a method and product for transdermal delivery of therapeutics, including neurotoxins and methods for use thereof. The method and system comprises pharmaceutical compositions for facilitating transdermal delivery of therapeutics without pain by absorption and more particularly a series of pharmaceutical formulations for topical administration of neurotoxins to humans, including a neurotoxin, such as a botulinum toxin, and absorption enhancing agents that facilitate absorption of the neurotoxin through the skin of the patient and do not eliminate the bioactivity associated with the neurotoxin. The pharmaceutical compositions are topically applied on a patient, and are generally in a cream or gel form.

Abstract: The present invention relates to a process for the preparation of colloidal systems, such as nanocapsules and nanoparticles, which incorporates a homogenization step for reducing particle size.

Abstract: The present invention relates to pharmaceutical compositions for the controlled release of lipocalin muteins and conjugates thereof with a moiety selected from the group consisting of a protein, protein domain, peptide, lipid, fatty acid, polysaccharide and/or an organic polymer that comprise said lipocalin mutein of conjugate thereof in combination with a biodegradable polymer. The invention further relates to a method for the controlled delivery of the lipocalin muteins or conjugates thereof, methods for the production of a controlled release formulation and the thus produced formulation.

Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.

Abstract: The present invention relates to a nanoscale or microscale container for encapsulation and delivery of materials or substances, including, but not limited to, cells, drugs, tissue, gels and polymers contained within the container, with subsequent release of the therapeutic materials in situ, methods of fabricating the container by folding a 2D precursor into the 3D container, and the use of the container in in-vivo or in-vitro applications. The container can be in any polyhedral shape and its surfaces can have either no perforations or nano/microscale perforations. The container is coated with a biocompatible metal, e.g. gold, or polymer, e.g. parylene, layer and the surfaces and hinges of the container are made of any metal or polymer combinations.

Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Abstract: The present invention includes fusion peptides comprising fragments of the cancer-related protein Her2/neu, methods of preparing such fusion peptides, virosomes comprising such fusion peptides, and uses of such fusion peptides or virosomes for the prevention, treatment or amelioration of a cancer characterized by expression or over-expression of the Her2/neu protein.

Abstract: The present invention relates to the use of spinosyns and spinosyn compositions as pharmaceuticals and methods for treatment—including prevention—of protozoan infections and/or disorders relating to a protozoan infection, such as malaria and leishmania, viral infections such as Herpes Simplex virus and Influenza virus and neoplastic disorders or cancer. Advantageously, compositions of the invention inhibit protozoan, virus growth and neoplastic cell proliferation with only minimal or no disruption or ham to the host which may be an animal or human.

Abstract: Preconcentrates comprising a fatty acid oil mixture and at least one surfactant, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.

Abstract: Nanocarriers and methods of preparation and use of nanocarriers are presented. In some embodiments, a nanocarrier composition comprises an organic liquid comprising a plurality of nanoparticles dispersed therein; and a coating material disposed around the exterior surface of the organic liquid. Biological tissue may be imaged or treated by coming into contact with a nanocarrier composition, and, at least in some embodiments, irradiated.

Abstract: The invention relates to an injectable biomaterial. The injectable biomaterial of the invention comprises a non aqueous solvent which is compatible for injection to human being and nanoparticles made of a polymer which is insoluble in water and insoluble in said non aqueous solvent, said nanoparticles being loaded with a drug or a biological agent. The injectable biomaterial of the invention is particularly appropriate for occluding normal or malformative blood vessels or non circulating cavities or for necrosing tumors.

Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.

Abstract: The invention encompasses nanoparticle assemblies and methods for preparing nanoparticle and compositions comprising such nanoparticles for use in topical or skin applications. The invention further encompasses methods of complexing various molecular and cellular entities to the nanoparticles using the resulting nanoparticles of the invention as delivery devices. The nanoparticles can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of a complexed agent in vivo, protecting a complexed agent against degradation, increasing skin penetration and retention of drugs, and enhancing the water solubility/dispersibility of a drug or other agent.

Abstract: Systems and methods are provided for filtering a fluid containing nanoparticles. The systems and methods generally include introducing a stream of the nanoparticle-containing fluid into a holding vessel, and extracting at least a part of a nanoparticle-containing fluid accumulated in the holding vessel. The extracted nanoparticle-containing fluid is passed through a filtration module to separate a nanoparticle-containing retentate from a permeate, and the retentate is returned to the vessel. The filtration cycle can be repeated until a desired concentration of the nanoparticles is achieved in the holding vessel. In many embodiments, the generation of the nanoparticle-containing fluid and its filtration are performed concurrently.

Abstract: Methods and formulations for treating a condition of the skin by delivering therapeutic formulations to the skin that translocates active substances across the stratum corneum barrier to a targeted skin tissue. The methods and formulations comprise active substances encapsulated within surface modified nanostructured lipid carrier nanoparticles.

Abstract: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.

Abstract: The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a copper (Cu)-based nanoparticle and a method for making the same. The Cu-based nanoparticles can further be incorporated with additional therapeutic or diagnostic compounds and used for the diagnosis and treatment of tumors.

Abstract: The present invention provides for methods of preparing silk nanoparticles and microparticles, methods of encapsulating an active agent into the silk nano- and microparticles and compositions comprising these silk particles. In particular, the silk spheres are prepared from phase separation of silk and polyvinyl alcohol (PVA), without exposure to an organic solvent. The method employs a chemical, PVA, which is an FDA-approved ingredient in drug formulations. Different parameters can be adjusted to control the size and shape of the silk spheres during the fabrication process. The silk particle compositions of the present invention may also encapsulate active agents or chemicals. Such compositions allow the active agents to be controllably and sustainably released to the target organs or tissues. The silk composition entrapping active agents also provides for a long-term storage medium for the active agents so entrapped.

Abstract: The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.

Abstract: A formulation comprising botulinum toxin (BT), lipid and surfactant, characterised in that the lipid and surfactant are in the form of macromolecular assemblies of less than 100 nm in diameter. The surfactant may have an HLB number of less than 20.

Abstract: Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy.

Abstract: A nanoparticle-based delivery system and methods for its use are disclosed. In one aspect, a nanoparticle-based delivery system comprising at least one molecule such as proteins, DNA/RNA or fragments thereof, carbohydrates, enzymes, chemicals, virus cells, bacteria, parts of a virus, parts of a bacteria, parts of a cell, part of a tissue, or a combination of one or more of these, which shall be referred to as immunogens, are chemically or physically combined with water soluble nanoparticles which, when administered to a living system, is capable of eliciting a desired immunological response. More particularly, the invention relates to nanoparticle-based delivery systems that are specifically engineered to enhance humoral or cellular immune response without the use of adjuvants.

Abstract: The present invention provides a carrier component. The carrier component includes a carrier core body including a dispersive object and a dualistic self-assembly material for encapsulating the dispersive object, wherein the dualistic self-assembly material has an electric charge; and a first shell layer having an electric charge opposite to the electric charge of the dualistic self-assembly material, and coating the carrier core body, and thus avoids inactivation of a medicine, eliminates medicine leakage and reduces medicine releasing. The present invention further provides a method for forming a carrier component.

Abstract: The present invention relates to methods for treating and completely curing fungal, yeast, and/or mold infections in human subjects comprising topically administering to a human subject in need thereof an antifungal nanoemulsion composition.

Abstract: The present invention relates to a photosensitizer-containing nanoparticle, comprising a photosensitizer covalently bonded throughout at least a part of said nanoparticle to the nanoparticle matrix material and incorporated therein in a quasi-aggregated state. The present invention further relates to methods for producing the invention nanoparticles, and to methods of killing cancer cells by PDT treatment using the said nanoparticles.

Abstract: The present application relates to Nanoparticle bioengineering techniques were used to produce a non-toxic polypyrrole composition having two-dimensional and three-dimensional structures that can optionally be co-polymerized with carboxylic acid moieties to possess hydrophilicity. Likewise, such polypyrrole/carboxylic acid structures may be further modified with neural growth factors to create treatment surfaces that can promote growth an differentiation of cells such as neurons.

Abstract: The present invention relates to a lipid nanoparticle system comprising a lipid component, a cationic surfactant, a non-ionic surfactant, a polysaccharide and, optionally, a positively charged peptide, useful for the release of pharmacologically active molecules, and especially for transfecting genetic material into cells and/or tissues. It also relates to methods for obtaining nanoparticles, to pharmaceutical compositions comprising it, as well as to the use thereof in gene therapy.

Abstract: Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis.

Abstract: A delivery system for water-insoluble pharmaceutical active ingredients is provided. The delivery system includes water-insoluble pharmaceutical active ingredient(s), organic solvent(s) and amphiphilic co-solvent(s), and a mixture of hydrophilic and hydrophobic non-ionic surfactants. Upon dilution in an aqueous medium, this formulation forms spontaneously dispersion of non-ionic surfactant nanoparticles.

Abstract: The present technology provides compositions with positively-charged poly(d,l-lactide-co-glycolide) nanoparticles capable of releasing a bioactive substance in a body tissue for extended periods of time, as well as methods for manufacture of the same and methods for prophylactic and therapeutic treatment of a subject in need thereof.

Abstract: The invention relates to the use of gingival fibroblasts for obtaining a cellular composition for treating arterial-remodelling pathology, for example an aneurysm, post-cryoplasty stenosis and restenosis, an aortic dissection or atherosclerosis.

Abstract: Immunostimulatory compositions include an isolated nucleic acid molecule that includes one or more nucleotide sequences from 5?- or 3?-terminal regions of positive-sense, single-stranded RNA virus genomes and/or or nucleotide sequences from a 5?-terminal regions of negative-sense, single-stranded RNA virus genomes.

Abstract: A delivery vehicle, for delivering a pharmaceutically active agent or a marker to a cell, comprising a ligand binding portion specific for a Fas Ligand, and a carrier for the pharmaceutically active agent or marker.

Abstract: An anesthesia delivery system comprising a nanosphere forming a bubble into which an anesthesia is introduced and delivered with a swab of absorbent material to a site to be treated.

Abstract: This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and meth-°ds of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts. X?NO2, Cl, Br, NH2, OH, H, alkyl at one or several o, m, and p positions R?H or alkyl.

Abstract: Highly fluorescent carbon nanoparticles (FCNs), with tunable emission colours of particle size between 1-10 nm also stable in solid form with high quantum yield (>5%) and its method of synthesis thereof yielding said carbon nanoparticles in milligram to gram scale in high synthesis yield (>80%). The present invention also provides for highly fluorescent carbon nanoparticle solution doped with heteroatom (such as oxygen, nitrogen) and its method of synthesis favoring yield of the said doped carbon nanoparticles of even smaller size ranging from 1-5 nm with narrow size distribution, and also provides for functionalized FCNs that are non-toxic, functional, soluble and stable fluorescent carbon nanoparticles with retained fluorescence for variety of end uses in biomedics, imaging applications, and detection techniques.

Abstract: This invention discloses a process for making nanoparticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in a nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired.

Abstract: Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided.

Abstract: The present invention is directed to delivery complexes of rosette nanotubes and one or more biologically active agents or diagnostic agents.

Abstract: This invention relates to compositions, and related compounds and methods, of conjugates of synthetic nanocarriers, or components thereof, and biologically active agents, such as immunomodulatory agents, antigens, anticancer agents or antiviral agents. The biologically active agents are released from the synthetic nanocarriers in the presence of a reducing agent or by reaction with a thiol.

Abstract: The disclosure relates to immunizing agents and devices.

Abstract: Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein peptides are bound to or associated with the nanoparticles.

Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.

Abstract: The present invention relates to a lyophilized nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilized nanoemulsion by redispersion, and to a process for the preparation of the lyophilized nanoemulsion.

Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.

Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.

Abstract: This invention provides a method for inducing immune tolerance toward an antigen comprising the antigen in lipidic particles or lipidic compositions. The lipidic particles are made up of phosphatidylserine and phosphatidylcholine, or phosphatidylinositol and phosphatidylcholine. The lipidic compositions comprise the antigen and O-phospho-L-serine. Administration of these composition results in inducing immune tolerance to the antigen.

Abstract: The invention relates to soluble selenium compositions and methods of production, separation and purification thereof. In particular the present invention provides methods of preparing water soluble selenoglycoproteins (e.g., via extracting selenoglycoproteins from selenium enriched yeast), methods of supplementing a selenium deficient composition via admixing water soluble selenoglycoproteins with the selenium deficient composition, compositions comprising the water soluble selenoglycoproteins and methods of administering the same.

Abstract: Compounds and methods are disclosed in which a prodrug can be delivered in an elevated oxidative state to cells by means of graphitic nanoparticles to which the prodrug is attached by a hydrophilic polymer and which have been made soluble by a hydrophilic polymer, such as PEG. The graphitic nanoparticle may be a single walled carbon nanotube (SWNT). The prodrug may be a DNA-binding metal-based drug. Exemplified is a platinum(IV) complex c,c,t-[Pt(NH3)2Cl2(OEt)(O2CCH2CH2CO2H)], which is nearly nontoxic to testicular cancer cells, but displays a significantly enhanced cytotoxicity profile when attached to the surface of amine-functionalized soluble SWNTs. An amine functionality on the hydrophilic polymer may be used to link the prodrug.